Background: Sorafenib is a multikinase-tyrosine kinase inhibitor commonly used in a variety of cancers. There are concerns about the increased risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib. We performed an upto-date meta-analysis of all phase 3 randomized controlled trials (RCTs) of sorafenib to quantify the increased risk of SAEs and FAEs.
Introduction
Molecular targeted drugs such as tyrosine kinase inhibitors (TKIs) represent a major advance in cancer treatment. Sorafenib is one of the most commonly used multitarget-TKIs and has gained approval in the treatment of metastatic or advanced liver [1] , kidney [2] and thyroid [3] cancers. However, sorafenib use is also associated with a variety of adverse effects including diarrhea, hypertension, hand-foot syndrome, acne, loss of appetite and other toxicities [4] . These toxicities of mild to moderate severity are common, frequently last long, can be debilitating and thus, decrease the quality of life of patients. Hence, these toxicities are frequently explained to the patients during informed consent before starting sorafenib treatment in clinical practice or clinical trials. Serious adverse events (SAEs) and fatal adverse events (FAEs) have both occurred in the clinical trials of sorafenib and have graver consequences to the patient, family and society. Unfortunately however, the incidence and risk of SAEs and FAEs are frequently overlooked during the treatment decision-making process due, at least partly, to lack of data. In addition to efficacy, SAEs and FAEs represent the information of utmost concern to any patient about to start on any therapy.
Hence, we performed this meta-analysis to estimate the incidence and risk of SAEs as well as FAEs with sorafenib among adult patients with solid tumors in phase 3 randomized clinical trials (RCTs).
Materials and methods
This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [5] .
Study selection and data extraction
We conducted an independent review of the PubMed database on February 2016 using the keyword 'sorafenib' OR 'nexavar'. Eligibility criteria included phase 3 RCTs in humans without any language or date restrictions. We also additionally performed searches of the Cochrane Database, Web of Science and Google Scholar databases to ensure no eligible studies were overlooked. After title/abstract screening by two independent investigators (B.G and T.S/K.H), the full texts of potentially relevant studies were downloaded and Methods and Results section reviewed for confirmation of eligibility criteria. When data on SAEs and FAEs were not available and/or were confusing, we tried to contact the corresponding author of the study for clarification. We included only the most recent and complete report when duplicate publications of same study were found.
Reviews, editorials, correspondences, phase 1 and phase 2 trials, nonrandomized studies were excluded. The aim of our study was to estimate the incidence and risk of SAEs and FAEs with the use of sorafenib compared with no or cytotoxic treatment among adult patients with solid tumors. We thus excluded studies involving pediatric patients, patients with hematological malignancies and RCTs comparing sorafenib with another VEGFR TKI or sorafenib in both the intervention and control cohorts. Studies that met the following criteria were included in the analysis: (i) prospective phase 3 RCTs involving patients with solid tumors, (ii) random assignment of participants to sorafenib or non-VEGF TKI control (placebo or best supportive care (BSC) or chemotherapy) alone or in combination with other treatment, and (iii) available data regarding events or incidence of SAEs, FAEs and sample size. The quality of reports of clinical trials were assessed using Jadad scale as previously described [6] . Relevant data were extracted independently by two reviewers (B.G and T.S/K.H) and verified by the third reviewer (T.S/K.H). Any discrepancy among reviewers was resolved with consensus.
The primary endpoint of the study was the incidence and relative risk (RR) of SAEs and FAEs with sorafenib. FAEs are defined as death caused in all likelihood by the drug and SAEs are defined as adverse events leading to death, life-threatening condition, hospitalization or prolongation of hospitalization, disability or permanent damage, congenital anomaly or birth defect, requiring intervention to prevent permanent impairment or damage, or any other adverse events that may jeopardize the patient and may require medical or surgical intervention (treatment) to prevent one of the other outcomes [7] . The attribution of SAEs or FAEs as treatment-related or disease-related depended on the decision of the primary investigators in the original trials. The data on 'treatment-related SAEs' and 'treatmentrelated FAEs' were extracted from the publications for the purpose of this meta-analysis.
Statistical analysis
All statistical analyses were performed using Comprehensive Metaanalysis software, version 3 (Biostat, Englewood). For the calculation of incidence, data on the number of patients with SAEs, the number of patients with FAEs and the number of patients receiving sorafenib were extracted from the publications of the selected clinical trials and the proportion of patients with SAEs and FAEs and 95% confidence intervals (CIs) were derived for each study. For the calculation of RR, patients assigned to sorafenib (6 chemotherapy) cohort were compared with those assigned to placebo/BSC (6 chemotherapy) cohort in the same trial. When studies reported zero events in a treatment or control arm, we used a classic half-integer continuity correction for the calculation of relative risk.
The pooled estimate for incidence and RRs were calculated using random-effects or fixed-effects model as appropriate depending on the heterogeneity of included studies. Assumption of homogeneity was considered to be invalid for values of P < 0.10 for the Cochrane Q statistic and the inconsistency was quantified with the I 2 statistic. When the assumption of homogeneity was considered invalid, random-effects model was used to pool the summary incidence and RRs otherwise fixed-effects model was used.
When heterogeneity was observed, possible reasons for the heterogeneity were explored by conducting subgroup analyses for both SAEs and FAEs. Subgroup analyses were pre-specified and included: tumor type, sorafenib use alone versus in combination with other chemotherapy (single versus combination), and sorafenib trials that led to approval for that indication (or were already approved) versus those that didn't (approval status).
As suggested in the Cochrane Handbook, we tried to limit the number of subgroup analyses [8] . No post hoc subgroup analyses were performed. The above subgroups were chosen for their clinical relevance and importance. In addition, subgroup analyses were not performed if there was no evidence to assume heterogeneity.
We also assessed publication bias for both SAEs and FAEs using Begg's [9] and Egger's tests [10] that complement the funnel plots.
Results

Study characteristics
Our search revealed a total of 471 potentially relevant studies of which 12 phase 3 RCTs fulfilled our eligibility criteria ( Figure 1 ) [1] [2] [3] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Of these, eight compared sorafenib versus placebo as single agents and four compared sorafenib plus chemotherapy versus placebo plus chemotherapy. Five RCTs were conducted in patients with hepatocellular carcinoma (HCC), two each in patients with melanoma and nonsmall cell lung cancer (NSCLC) and one each in patients with pancreatic cancer, renal cell cancer (RCC) and thyroid cancer. Overall, only 4 of the 12 RCTs led to or were in accordance with the approval status of sorafenib (Tables 1 and 2 ).
Study quality
We graded the quality of each study included in this metaanalysis using the 7-item Jaded score that provides a score between 0 and 5 for each study (studies with score of 4 and 5 indicating good quality studies). All studies included in this metaanalysis had a score of 4 or 5 indicating good quality ( Table 2 ). All the studies were double-blind, placebo-controlled RCTs and included data on FAEs and SAEs except for the Flaherty study HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; NSCLC, nonsmall cell lung cancer; Adv., advanced/metastatic disease; 1L, first line; 2L, second line; PFS, progression-free survival; OS, overall survival; HR, hazard ratio.
[13] that lacked SAE data. This data was unavailable even after contacting the study author.
Patients
A total of 6797 patients were randomized in the 12 phase 3 RCTs included in this meta-analysis, of which 3429 patients were assigned to sorafenib and the rest to control treatment (Table 1 ). All the patients in these studies had a performance status (PS) between 0 and 2. Sorafenib was used at a dose of 400 mg twice daily in all the included trials. Safety population consisted of 6577 patients (Sorafenib: 3314, control: 3263) of which the majority had HCC (n ¼ 2435), NSCLC (n ¼ 1664) and melanoma (n ¼ 1058) ( Table 2 ). The safety population includes all those patients who were exposed to at least one dose of the treatment.
Incidence of SAEs and FAEs
All but one study reported data on SAEs (Flaherty et al. [13] did not include data on SAEs and was excluded from the analysis of SAEs) while all studies reported data on FAEs. Thus, 2921 patients receiving sorafenib from 11 studies were included for the analysis of incidence of SAEs. Of them, 748 patients in total experienced SAEs. Using random-effects model (significant heterogeneity, Q ¼ 284.39, P < 0.001, I
2 ¼ 96.5%), the summary incidence of SAEs in patients receiving sorafenib was 26.4% (95% CI, 18.0-36.9%). The incidence of SAE was highest in the Goncalves study [15] (66.0%) and lowest in the Cheng study [20] (8.7%). The incidence of SAEs varied significantly with cancer type (P < 0.001), single versus combination use (P ¼ 0.042) and approval status (P < 0.001). The summary incidence rates in various tumor types in decreasing order were pancreatic cancer (66.0%), metastatic melanoma (43.3%), thyroid (37.2%), RCC (34.1%), NSCLC (20.0%) and HCC (17.1%) ( Table 3) .
3314 patients from 12 studies were included for the analysis of incidence of FAEs. No FAEs occurred in five RCTs. A total of 37 patients among 3314 experienced FAEs. Again a random-effects model was employed (heterogeneity test, Q ¼ 81.11, P < 0.001, I 2 ¼ 86.4%). The summary estimate for the incidence of FAEs was 1.3% (95% CI, 0.8-2.2%). The incidence of FAEs differed significantly with cancer type (P¼ 0.007) and approval status (P ¼ 0.002) but not with single versus combination (P ¼ 0.368). The summary incidence rates in various tumor types in decreasing order were metastatic melanoma (2.5%), NSCLC (2.4%), pancreatic cancer (2.0%), HCC (0.6%), thyroid (0.5%) and RCC (0.1%) ( Table 3) .
RR of SAEs and FAEs
The summary RR of developing a sorafenib-related SAE among the 5787 patients from 11 studies was 1.49 (95% CI, 1.18-1.89, 
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Annals of Oncology P ¼ 0.001; incidence 26.4% versus 17.6%, Figure 2 ). This estimate was obtained by pooling the data using random effects model as the tests suggested a significant heterogeneity in the increased risk of SAEs with sorafenib (Q ¼ 52.94, P < 0.001, I 2 ¼ 81.1%). The cause for heterogeneity was again explored based on pre-specified subgroup analysis. The RR of developing SAEs with sorafenib differed significantly with cancer type (P < 0.001) and approval status (P ¼ 0.012) but not single versus combination use (P ¼ 0.438). The risk for SAEs was significantly higher for HCC (RR 1.86, 95% CI 1.03-3.38, P ¼ 0.040) and nonapproval use of sorafenib (RR 1.63, 95% CI 1.19-2.21, P ¼ 0.002). The risk for SAEs with various tumor types in decreasing order were NSCLC (RR 1.96), HCC (RR 1.86), thyroid (RR 1.41), RCC (RR 1.40), pancreatic cancer (RR 1.11) and melanoma (RR 0.92) but the increased risk was significant only for HCC.
The summary RR of developing a sorafenib-related FAE among the 6577 patients from 12 studies was 1.82 (95% CI, 1.05-3.14, P ¼ 0.033; incidence 1.3% versus 0.7%, Figure 3 ). This estimate was obtained by pooling the data using fixed-effects model as no significant heterogeneity was detected for the increased risk of SAEs with sorafenib (Q ¼ 4.268, P ¼ 0.961, I
2 ¼ 0.0%). Because no heterogeneity was observed, subgroup analyses were not done for FAEs. To account for any possible clinical heterogeneity not detected by statistical tests, we also pooled the data using randomeffects model: the RR and 95% CI remained unchanged.
To account for the improvement in management of adverse effects with sorafenib over time, we also assessed whether the risk of SAEs and FAEs had any significant relationship with the time of RCTs. We could not observe any consistent patterns of decrease or increase in the risks of either SAEs or FAEs with time (data not shown). Hence, any bias in the assessment of risk of SAEs and FAEs due to poor management of adverse events in the earlier period may be ruled out.
Specific types of FAEs
The Flaherty study [13] didn't mention the specific types of FAEs but all other studies with FAE events did. This information couldn't be obtained even by contacting the lead author. From the available data, the commonest cause of sorafenib related FAE was hemorrhage in 6 (lung 4, abdominal 1, respiratory tract 1), respiratory failure/insufficiency including dyspnea and pneumonia in 5, cerebral events in 3 (hemorrhage in 2, edema in 1), liver failure in 3, cardiac events in 2, thrombotic events in 2, neutropenic sepsis in 2, one each of pulmonary embolism, GI perforation and renal failure, and 2 not otherwise specified. These specific types of FAEs showed some relationship with the underlying disease. All deaths due to hemorrhage, thrombotic events, respiratory failure, pulmonary embolism, GI perforation and renal failure occurred among patients with NSCLC while deaths due to liver failure occurred only among patients with HCC. Similarly, both deaths due to neutropenic sepsis were among patients with melanoma while cerebral events occurred in patients with melanoma, pancreatic cancer and HCC. Cardiac events occurred in patients with thyroid cancer and NSCLC.
Publication bias
There was no evidence of publication bias for FAEs by either the Begg's test (P ¼ 0.22) or the Egger's test (P ¼ 0.64). However, 
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This meta-analysis shows significantly increased risk of treatment-related SAEs and FAEs among patients with solid tumors enrolled in phase 3 RCTs of sorafenib. The risk increased by as much as 49% for SAEs and 82% for FAEs. Although the actual incidence of FAEs was relatively low at 1.3%, SAEs developed in as many as more than one-fourth of all patients receiving sorafenib. These findings have important clinical implications.
Cancer treatment with modern targeted therapies is a double edged sword. Patients frequently tend to overestimate the benefit of treatment and downplay the harms [21] . Therefore, the discussion of the adverse effects should play a major role in the decisionmaking process in oncology clinic. SAEs lead not only to treatment interruption or discontinuation but also to hospitalizations, disabilities and deaths. The information on SAEs should therefore form an important aspect of shared decision-making. Without proper understanding of the risks of SAEs, a patient and his/her clinician won't be able to properly judge the risk-benefit balance. We show that with sorafenib treatment, more than one-fourth of patients develop SAEs. In addition, 1.3% of patients die due to adverse effects of treatment alone. These data should be important in considering the trade-off of sorafenib treatment for solid tumors.
There have been a few meta-analyses estimating FAEs with VEGFR inhibitors. The anti-VEGF antibody bevacizumab was shown to increase the risk of FAEs by 33% [22] . Another metaanalysis of VEGFR-TKIs, including 6 sorafenib studies, showed >2-fold increase in the risk of FAEs [23] . In the sorafenib subgroup of this meta-analysis, the incidence of FAEs was 1.4% among the 1472 patients, very similar to our own estimate of 1.3% among 3314 patients in our current study. However, the RR was 2.68, much larger than our estimate of 1.82. This shows that, although the incidence of FAEs is similar, the RR gets exaggerated when comparison is made among small number of patients as a subgroup analysis.
Two other meta-analyses have tried to explore the risk of FAEs with sorafenib. One meta-analysis included only three trials of sorafenib among other VEGF-TKIs [24] while the other, although including 13 trials, ignored trials with zero events during the pooling process [25] . It has been recommended that studies with zero events not be excluded from meta-analyses [26, 27] . Furthermore, this study included five small phase 2 trials among them, and information from new trials hasn't been incorporated. Our current meta-analyses including 6797 patients from high quality phase 3 RCTs is thus the largest meta-analysis of sorafenib-related FAEs in adult patients with solid tumors and provides a reliable quality evidence for judging the risk-benefit ratio of treatment with sorafenib. Our study is also the first meta-analysis to report on incidence and risks of SAEs with any targeted therapies.
Although there was heterogeneity in the incidence of both SAEs and FAEs, there was no heterogeneity in the risk of FAEs.
We also found heterogeneity in the risk of SAEs, but not FAEs. The risk of SAEs was significantly increased in nonapproval studies, i.e. studies that used sorafenib in settings that is not currently approved. The reason for this is not clearly known, because the dose and schedule were the same across the included studies. However, this finding should discourage the off-label use of sorafenib. This could be particularly important because off-label studies of targeted drugs are getting more common recently. It is reassuring that the risk for SAEs didn't increase significantly in the subgroup of trials that led to drug approval or was used in post-approval setting. Our meta-analyses also showed that the risk for SAEs was higher among patients with HCC but not other histological types. HCC patients have poor liver function and this could explain this difference, at least partly. Nevertheless, all these findings are only hypothesis generating, being subgroup analysis.
A proper discussion of risk-benefit of treatment with sorafenib should include the strength of evidence, the estimate of benefit, as well as the likelihood of SAEs and FAEs. The patient should understand the risks s/he is accepting when consenting to any treatment. Our meta-analysis will hopefully ease the decision-making process by providing relevant information in terms of absolute incidence and increased relative risk. The development of predictive markers of sorafenib would improve the benefit-harm balance.
Inclusion of well-conducted, good quality, phase 3 RCTs are the strengths of our study. The lack of heterogeneity in the risk evaluation of FAEs represents a well selection of studies. Furthermore, we limited our subgroup analyses to a minimum and were all pre-planned. Inclusion of large number of patients and recent studies are other strengths.
Several limitations apply to our study. One obvious limitation is that the risk estimates it provides are trial-level estimates and confounders at patient-level precludes the generalizability of these findings to the patient in clinic. Further, this is a summary estimate from good quality well-conducted phase 3 RCTs and thus, the real risk in a real-life patient with comorbidities and poor PS could be higher. Indeed, in a recent real-world analysis of sorafenib in HCC, the survival benefit in real-world population was found to be much less than that mentioned in the pivotal trial [28] . In addition, one could argue that the difference in treatment durations would create bias in the assessment of risk with sorafenib. However, as seen from Table 2 , the median duration of treatment was shorter for the sorafenib cohort among 'nonapproval' studies that had higher incidences of SAEs and FAEs. Hence, the increase in risks of SAEs and FAEs with sorafenib in this study may not be attributed to differences in treatment duration. In addition, SAEs and FAEs were not the primary endpoint of any of the trials included in this meta-analysis. So, the labeling of SAEs and FAEs as treatmentrelated or disease-related by the study investigator could bias the results. Furthermore, although all the studies were double-blind, experienced physicians might easily recognize the adverse effects of sorafenib versus control leading to bias. In addition, the unavailability of SAE and details of types of FAEs data from one study [13] as well as the detection of publication bias in the meta-analysis of SAE are other limitations of our meta-analysis. In case of TARGET study, the publication reports the number of FAEs as 46 and 25 in sorafenib and placebo cohorts, respectively, but the publication report is not clear regarding whether those FAEs were treatment related. Upon contacting the lead author we found that treatment related mortality was zero in both the groups. It is important to note that previous meta-analyses that included this study have taken quite different data for FAEs: 46 and 25 [25] , 2 and 1 [23] and 36 and 18 [24] as FAE events. This highlights the need for providing unambiguous information on the study publication for such important data, as well as the importance of confirming ambiguous data with the study author while conducting any metaanalysis.
In conclusion, sorafenib significantly increases the risk of serious and fatal drug-related adverse events. Sorafenib has also shown important clinical benefits in cancers such as HCC, RCC and thyroid cancers. These risks should be properly weighed against the clinical benefit provided by sorafenib and discussed with the patient. For patients who decide to be on sorafenib, appropriate care should be taken to prevent SAEs and FAEs. Offlabel use of sorafenib should be discouraged.
